Open AccessNeonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir
Author(s) -
Bedangshu Saikia,
Julian W. Tang,
Simon Robinson,
Sanjiv Nichani,
Kelly-Beth Lawman,
Mahesh Katre,
Srini Bandi
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003081
Subject(s) - medicine , disease , guideline , mechanical ventilation , pediatrics , multidisciplinary team , assisted ventilation , covid-19 , presentation (obstetrics) , intensive care medicine , surgery , infectious disease (medical specialty) , anesthesia , pathology , nursing
We describe 2 expremature infants presenting with SARS-CoV-2-related pulmonary disease in their second and fifth week of life needing support with mechanical ventilation. Both infants' initial presentation was with repeated apneas. These cases highlight that SARS-CoV-2 infection could present with apneas and has the potential to progress to more severe pulmonary disease in this high-risk age group of patients. Both patients were treated with remdesivir (RDV). We provide the data of 2 high-risk neonates successfully treated with RDV without observation of any described side effects. A recognition that these high-risk neonates could deteriorate and early multidisciplinary team discussion is the mainstay to the compassionate access to RDV. Our experience led us to develop a guideline on the use of RDV below 12 years of age, with particular focus on infants and young children.